Diffuse midline glioma, H3 K27-altered
MONDO:1060171A diffuse midline glioma characterized by H3 K27 alteration and usually either a histone H3 K27M mutation, an EGFR mutation, or aberrant overexpression of EZHIP. The prognosis is poor.
Also known as: DMG, H3 K27-altered
3088 clinical trials for this condition and its sub-types, 11 tagged with Diffuse midline glioma, H3 K27-altered itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diffuse midline glioma, H3 K27-altered
-
Diffuse midline glioma, H3 K27M-mutant 31 trials
-
New hope for kids with deadly brain tumors: ACT001 trial launches
Disease control Recruiting nowThis study tests an experimental drug called ACT001 in children and young adults (ages 1 to 39) with two aggressive brain tumors: DIPG and H3K27-altered high-grade gliomas. The goal is to see if ACT001 can improve survival or shrink tumors after radiation therapy. About 60 partic…
Phase 2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Nasal spray could deliver brain tumor treatment directly to Kids' tumors
Disease control Recruiting nowThis early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…
Phase 1 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for kids with relapsed cancers: experimental drug CBL0137 enters trial
Disease control Recruiting nowThis study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…
Phase 1/2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for kids with DIPG: major trial compares two treatments
Disease control Recruiting nowThis phase 3 trial tests whether the drug ONC201 works better than everolimus for children and adults with DIPG, a rare and aggressive brain tumor. About 433 participants will receive one of the two drugs, and can switch if their disease gets worse. The goal is to see which drug …
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Targeted drug lorlatinib tested in kids with rare brain tumors
Disease control Recruiting nowThis early-phase study tests the drug lorlatinib in children and young adults (ages 1 to 21) with newly diagnosed high-grade glioma, a fast-growing brain tumor, that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor…
Early phase 1 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for kids with deadly brain cancer? drug ONC206 enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ONC206 in children and young adults with diffuse midline glioma or other recurrent brain tumors. The drug aims to kill cancer cells by causing stress in them, without harming healthy cells. Researchers are looking for the safest dose…
Phase 1 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Radioactive drug targets brain tumors in early trial
Disease control Recruiting nowThis early-phase study tests a radioactive drug called 177Lu-PSMA-617 combined with standard chemotherapy (temozolomide) for people with aggressive IDH wild type gliomas. The goal is to see if the combination is safe and to get a first look at whether it helps control tumor growt…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for deadly brain tumors: Drug-Radiation combo trial opens
Disease control Recruiting nowThis study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is t…
Phase 2 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC